Alantolactone selectively ablates acute myeloid leukemia stem and progenitor cells
View/ Open
Author
Ding, Yahui
Gao, Huier
Zhang, Yu
Li, Ye
Gao, Yingdai
Chen, Yue
Zhang, Quan
Note: Order does not necessarily reflect citation order of authors.
Published Version
https://doi.org/10.1186/s13045-016-0327-5Metadata
Show full item recordCitation
Ding, Yahui, Huier Gao, Yu Zhang, Ye Li, Neil Vasdev, Yingdai Gao, Yue Chen, and Quan Zhang. 2016. “Alantolactone selectively ablates acute myeloid leukemia stem and progenitor cells.” Journal of Hematology & Oncology 9 (1): 93. doi:10.1186/s13045-016-0327-5. http://dx.doi.org/10.1186/s13045-016-0327-5.Abstract
Background: The poor outcomes for patients diagnosed with acute myeloid leukemia (AML) are largely attributed to leukemia stem cells (LSCs) which are difficult to eliminate with conventional therapy and responsible for relapse. Thus, new therapeutic strategies which could selectively target LSCs in clinical leukemia treatment and avoid drug resistance are urgently needed. However, only a few small molecules have been reported to show anti-LSCs activity. Methods: The aim of the present study was to identify alantolactone as novel agent that can ablate acute myeloid leukemia stem and progenitor cells from AML patient specimens and evaluate the anticancer activity of alantolactone in vitro and in vivo. Results: The present study is the first to demonstrate that alantolactone, a prominent eudesmane-type sesquiterpene lactone, could specifically ablate LSCs from AML patient specimens. Furthermore, in comparison to the conventional chemotherapy drug, cytosine arabinoside (Ara-C), alantolactone showed superior effects of leukemia cytotoxicity while sparing normal hematopoietic cells. Alantolactone induced apoptosis with a dose-dependent manner by suppression of NF-kB and its downstream target proteins. DMA-alantolactone, a water-soluble prodrug of alantolactone, could suppress tumor growth in vivo. Conclusions: Based on these results, we propose that alantolactone may represent a novel LSCs-targeted therapy and eudesmane-type sesquiterpene lactones offer a new scaffold for drug discovery towards anti-LSCs agents. Electronic supplementary material The online version of this article (doi:10.1186/s13045-016-0327-5) contains supplementary material, which is available to authorized users.Other Sources
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5034521/pdf/Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAACitable link to this page
http://nrs.harvard.edu/urn-3:HUL.InstRepos:29407735
Collections
- HMS Scholarly Articles [17928]
Contact administrator regarding this item (to report mistakes or request changes)